New Possibilities for Hormonal Vaginal Treatment in Menopausal Women
Hormonal vaginal therapy is an effective treatment option for women who experience vaginal symptoms related to hormonal changes. Estrogen and prasterone are widely used as vaginal treatments, particularly for urogenital atrophy. These symptoms may include vaginal dryness, itching, burning, and pain...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/14/4740 |
| _version_ | 1797588807915143168 |
|---|---|
| author | Katarzyna Tomczyk Karolina Chmaj-Wierzchowska Katarzyna Wszołek Maciej Wilczak |
| author_facet | Katarzyna Tomczyk Karolina Chmaj-Wierzchowska Katarzyna Wszołek Maciej Wilczak |
| author_sort | Katarzyna Tomczyk |
| collection | DOAJ |
| description | Hormonal vaginal therapy is an effective treatment option for women who experience vaginal symptoms related to hormonal changes. Estrogen and prasterone are widely used as vaginal treatments, particularly for urogenital atrophy. These symptoms may include vaginal dryness, itching, burning, and pain during sexual intercourse, all of which can significantly affect a woman’s quality of life. Previous studies have indicated that such treatment improves tissue elasticity, moisturizes the vagina, and can have a substantial impact on urine incontinence and vaginal microflora and decreases dyspareunia. Hormonal therapy is also useful and commonly used before vaginal surgical treatment. Prasterone is quite a new option for vaginal therapy in Poland and is mainly recommended for dyspareunia in menopausal women. The study related to prasterone therapy emphasizes its effectiveness and safety, making it advantageous to explore its beneficial impact. This paperwork aims to summarize the mechanism of action as well as the effects of both drugs and their beneficial action during vaginal treatment. |
| first_indexed | 2024-03-11T00:57:19Z |
| format | Article |
| id | doaj.art-08105a03e5a94f51af527b26920bbb83 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T00:57:19Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-08105a03e5a94f51af527b26920bbb832023-11-18T19:53:15ZengMDPI AGJournal of Clinical Medicine2077-03832023-07-011214474010.3390/jcm12144740New Possibilities for Hormonal Vaginal Treatment in Menopausal WomenKatarzyna Tomczyk0Karolina Chmaj-Wierzchowska1Katarzyna Wszołek2Maciej Wilczak3Department of Maternal and Child Health, Poznan University of Medical Sciences, 33 Polna Street, 60-535 Poznań, PolandDepartment of Maternal and Child Health, Poznan University of Medical Sciences, 33 Polna Street, 60-535 Poznań, PolandDepartment of Maternal and Child Health, Poznan University of Medical Sciences, 33 Polna Street, 60-535 Poznań, PolandDepartment of Maternal and Child Health, Poznan University of Medical Sciences, 33 Polna Street, 60-535 Poznań, PolandHormonal vaginal therapy is an effective treatment option for women who experience vaginal symptoms related to hormonal changes. Estrogen and prasterone are widely used as vaginal treatments, particularly for urogenital atrophy. These symptoms may include vaginal dryness, itching, burning, and pain during sexual intercourse, all of which can significantly affect a woman’s quality of life. Previous studies have indicated that such treatment improves tissue elasticity, moisturizes the vagina, and can have a substantial impact on urine incontinence and vaginal microflora and decreases dyspareunia. Hormonal therapy is also useful and commonly used before vaginal surgical treatment. Prasterone is quite a new option for vaginal therapy in Poland and is mainly recommended for dyspareunia in menopausal women. The study related to prasterone therapy emphasizes its effectiveness and safety, making it advantageous to explore its beneficial impact. This paperwork aims to summarize the mechanism of action as well as the effects of both drugs and their beneficial action during vaginal treatment.https://www.mdpi.com/2077-0383/12/14/4740prasteroneestrogenatrophy |
| spellingShingle | Katarzyna Tomczyk Karolina Chmaj-Wierzchowska Katarzyna Wszołek Maciej Wilczak New Possibilities for Hormonal Vaginal Treatment in Menopausal Women Journal of Clinical Medicine prasterone estrogen atrophy |
| title | New Possibilities for Hormonal Vaginal Treatment in Menopausal Women |
| title_full | New Possibilities for Hormonal Vaginal Treatment in Menopausal Women |
| title_fullStr | New Possibilities for Hormonal Vaginal Treatment in Menopausal Women |
| title_full_unstemmed | New Possibilities for Hormonal Vaginal Treatment in Menopausal Women |
| title_short | New Possibilities for Hormonal Vaginal Treatment in Menopausal Women |
| title_sort | new possibilities for hormonal vaginal treatment in menopausal women |
| topic | prasterone estrogen atrophy |
| url | https://www.mdpi.com/2077-0383/12/14/4740 |
| work_keys_str_mv | AT katarzynatomczyk newpossibilitiesforhormonalvaginaltreatmentinmenopausalwomen AT karolinachmajwierzchowska newpossibilitiesforhormonalvaginaltreatmentinmenopausalwomen AT katarzynawszołek newpossibilitiesforhormonalvaginaltreatmentinmenopausalwomen AT maciejwilczak newpossibilitiesforhormonalvaginaltreatmentinmenopausalwomen |